Novo Nordisk signed a global licensing agreement with Swedish drug-delivery company Nanexa worth up to €1.165 billion ($1.3 billion) to develop longer-lasting injectable treatments for obesity, type 2 diabetes, and other cardiometabolic conditions, the companies said Friday.
Under the agreement, Novo gains exclusive access to Nanexa’s PharmaShell technology, a system that coats individual drug particles with an ultra-thin inorganic layer to modulate their release profile over time. The agreement covers up to five development programs, with monthly and quarterly dosing as the target administration profiles, the company said.
Nanexa is eligible to receive €615 million in upfront payment and development and regulatory milestones, with the remainder tied to sales milestones. Novo will also owe Nanexa low single-digit royalty payments calculated against worldwide net sales of any products that reach market under the collaboration, the company said. Novo will lead global development and commercialization.
“We are very excited about and proud of this license agreement with Novo and look forward to working with them to successfully develop products with less frequent dosing in obesity and type 2 diabetes indications,” Nanexa CEO David Westberg said in a statement.
Nanexa Chairman Göran Ando said the deal gives the company the financial footing to expand its technology into additional therapeutic areas and advance internal programs further before seeking future partnerships. “It will also allow us to take new projects further in development before partnering which will generate financially very attractive potential future partner deals,” Ando said in a statement.
Nanexa stock more than doubled in early trading in Stockholm on Friday after the deal was announced. The Uppsala-based company reported full-year revenues of approximately $3.89 million for 2025, according to CNBC.
The deal comes as Novo works to defend and expand its position in the obesity drug market. The company set out its 2030 strategic ambitions earlier this week at a Capital Markets Day in London, outlining targets including bringing more than five drugs with multi-blockbuster potential to market by 2030 and reaching more than 60 million patients worldwide. The plan disappointed investors, sending Novo stock down as much as 7% on Monday. Novo also acknowledged that semaglutide — the active ingredient in its Wegovy and Ozempic products — will begin losing patent exclusivity in the early 2030s.